Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CodaVax
- Development stage
- Phase 1
- Lead developer
- Codagenix
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
CodaVax (specifically CodaVax-H1N1) is a live-attenuated influenza vaccine developed by Codagenix using its proprietary Synthetic Attenuated Virus Engineering (SAVE) platform. The platform utilizes a computer algorithm to recode the viral genome through codon deoptimization, introducing hundreds of mutations that use naturally non-preferred codons. This process attenuates the virus while maintaining all native antigens, aiming to elicit broad cellular and humoral immune responses without causing disease. Administered intranasally, CodaVax-H1N1 is designed to provide protection against divergent H1N1 strains and is produced via cell-based manufacturing, bypassing the limitations of egg-based production.
- Brand names
- CodaVax
- Other names
- CodaVax-H1N1CodaVax-H-1N1CodaVax-H 1N1
02
Targets
Sialoglycan (Cell-surface sialoglycan)H1N1 (Influenza A virus H1N1)
Beyond the preview
Go deeper on CodaVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CodaVax.